Miraj Sanghvi
Partner @ DigiTx Partners
San Francisco, United States
Miraj Sanghvi is a Partner at DigiTx Partners and comes with over 7 years of data science and operations experience at healthcare and early-stage companies. Before joining the firm, he served as a Senior Data Scientist at VigLink building machine learning models on terabytes of data in a production environment, while managing the data engineeringplatform. Miraj started his career as a Healthcare Policy Consultant working with Medicare and Medicaid on their Part D prescription drug program and brings additional experience from the healthcare industry having worked at a microbiology lab, as a researcher on a clinical trial, and as a research collaborator contributing on the development of a pediatric risk score. Miraj completed the Specialized Sciences Program at the University of Pennsylvania and holds a B.S. in Economics from Washington University in St. Louis.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Miraj Sanghvi invests in
Stages Miraj Sanghvi invests in
Countries Miraj Sanghvi invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (67%)
- Therapeutics 2 (67%)
- SaaS 1 (33%)
- Medical 1 (33%)
- Internet 1 (33%)
Stage
- Series A 2 (67%)
- Seed 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ciba Health
|
Ciba Health is a personalized digital therapeutics and virtual care platform. The company utilizes a precision health approach to treat and reverse chronic conditions while optimizing the physical and mental well-being of our patients | $10M / Series A / Dec 04, 2023 | |
Phluence
|
LifeLink is the conversational engagement platform for healthcare. We work with some of the largest healthcare systems and pharma companies in the country to reach their patients on mobile and messaging, with personalized, natural, and contextual conversations. LifeLink chatbots automate thousands of high-value patient touchpoints before, during,and after healthcare visits, resulting in improved operational efficiency, increased customer satisfaction, and superior brand loyalty. | $9.8M / Series A / Mar 30, 2021 | |
nQ Medical
|
nQ Medical is a digital therapeutics company addressing neurocognitive and neuromotor disorder via 24/7, passive data collection via personal devices. It is a frictionless, non-invasive, early detection, remote disease progression monitoring, and therapeutic measurement modality. nQ uses an artificial intelligence company to developcomputational biomarkers that have been proven in five years of clinical trials to substantially change the way disease is managed for a wide range of neuromotor and neurocognitive disorders (Alzhemer's, Parkinson's, Multiple Sclerosis, ALS, concussion, et al. The platfomr focuses on analysis of user interaction with common electronic devices to capture functional decline related to neurodegenerative disorders. The fine control of typing and touch screen kinematics together with the frequent use of electronic devices allows for precise monitoring of small changes in neurodegeneration that frequently go unnoticed by clinicians. nQ allows for early detection of disease, 24/7, passive, at home, remote monitoring of disease progression and the measurement of impact of therapy at a fraction of the cost of current gold standards. There is no required task. Just use your device as your would normally use it. Of note, as one of the company's medical advisors, Zoltan Mari, MD, of the Cleveland Clinic, so aptly quoted: "As important as it is to fund novel compounds for treating diseases, it is also important to set the stage for maximum impact when those compounds are discovered and approved for use. It is impossible to find a cure without early detection. That's why drug candidates fail. When the FDA puts its stamp on the first disease modifying drugs, such early detection technologies will be instantly necessary." He goes on to state further: "We also need a disease progression marker. Nothing so far has managed to do very well (while being profoundly expensive). Much of our research and clinical interest is turning toward disease progression. All efforts should focus on readying and perfecting early detection tools and building effective, reliable, inexpensive ways of tracking disease and the impact of therapy over time.” nQ is that early detection, disease progression computational biomarker. | $2.7M / Seed / Nov 18, 2019 |
Co-Investors
About DigiTx Partners
At DigiTx Partners,we believe that the pace of change in healthcare will only accelerate in the coming years. We believe that there are many smart people with great insights and drive who are developing innovative technologies and solutions. We look forward to supporting innovative companies that will make a difference in our healthcareecosystem, from companies that will change how patients navigate the healthcare system, that will integrate the disparate elements that comprise both diagnosis and treatment, that will speed the development of more effective drugs and that will enhance and enable efficient and accurate physician-patient interaction. DigiTx Partners looks forward to investing in those digital health companies that strive to keep all of us in better health.
DigiTx Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
David Kim
CEO & Managing Director
|
|||
|
Miraj Sanghvi
Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Miraj Sanghvi invest in?
Miraj Sanghvi invests primarily in Health Care, Therapeutics and SaaS startups, most often at Series A and Seed stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Miraj Sanghvi?
Public channels for Miraj Sanghvi include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Miraj Sanghvi last invest?
The most recent investment recorded for Miraj Sanghvi closed in Dec 2023. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
